Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CardlyticsCDLX -3.60%30 3-Year EPS without NRI Growth Rate is 43.20% as of Jun. 2026, which is 44% above its 10-year median of 29.90. GuruFocus rates CDLX with a GF Score™ of 30/100 and a GF Value™ of $13.84 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 713 Media - Diversified companies, Cardlytics ranks better than 83.31% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 43.20% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 24.60% per year.
During the past 10 years, the average EPS without NRI Growth Rate was 16.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 11 years, the highest 3-Year average EPS without NRI Growth Rate of Cardlytics was 71.70% per year. The lowest was -182.30% per year. And the median was 29.90% per year.
Cardlytics (NAS:CDLX) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Cardlytics 3-Year EPS without NRI Growth Rate Related Terms
CDLX vs WIMI, ACCS, MOBQ: 3-Year EPS without NRI Growth Rate Comparison
For the Advertising Agencies subindustry, Cardlytics's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cardlytics 3-Year EPS without NRI Growth Rate vs Media - Diversified Industry
For the Media - Diversified industry and Communication Services sector, Cardlytics's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Cardlytics's 3-Year EPS without NRI Growth Rate falls into.
Cardlytics 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 43.20% mean?
Cardlytics (CDLX) has a 3-Year EPS without NRI Growth Rate of 43.20% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Cardlytics and its competitors. This is 44% above median its historical median of 29.90. According to the industry distribution chart, Cardlytics ranks #119 out of 713 companies in the Media - Diversified industry, placing it in the top 16.7%.
Is Cardlytics' 3-Year EPS without NRI Growth Rate too high?
Cardlytics' current 3-Year EPS without NRI Growth Rate of 43.20% is 44% above median its 10-year median of 29.90. The Media - Diversified industry median 3-Year EPS without NRI Growth Rate is 3.70. Cardlytics' value of 43.20% is 1067.6% above this industry median. Based on the distribution chart, Cardlytics ranks #119 out of 713 companies in the Media - Diversified industry, which is in the top quartile — a strong position relative to peers. Overall, Cardlytics has a GF Score™ of 30/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cardlytics' 3-Year EPS without NRI Growth Rate compare to WIMI and ACCS?
According to the Media - Diversified industry distribution chart, Cardlytics ranks #119 out of 713 companies for 3-Year EPS without NRI Growth Rate. This places Cardlytics in the top 17% of its industry — outperforming the majority of peers. The industry median 3-Year EPS without NRI Growth Rate is 3.70. Cardlytics' value of 43.20% is 1067.6% above this benchmark. While the company's 10-year median is 29.90 vs. the industry median of 3.70, Cardlytics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Media - Diversified company?
The median 3-Year EPS without NRI Growth Rate among Media - Diversified companies is 3.70, based on 713 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cardlytics's current 3-Year EPS without NRI Growth Rate of 43.20% is 1067.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Cardlytics and its competitors. For the Media - Diversified industry, the median 3-Year EPS without NRI Growth Rate is 3.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cardlytics's current 3-Year EPS without NRI Growth Rate is 43.20%, which is 44% above median its own 10-year median of 29.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardlytics stock overvalued right now?
Based on GuruFocus' analysis, Cardlytics (CDLX) is currently considered Possible Value Trap. The stock's GF Value™ is $13.84, compared to a current price of $3.75 — trading 72.9% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 43.20%, which is 44% above median its 10-year median of 29.90 and 1067.6% above the Media - Diversified industry median of 3.70. Cardlytics' overall GF Score™ is 30/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Cardlytics (CDLX), the current 3-Year EPS without NRI Growth Rate is 43.20% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cardlytics (CDLX) Overvalued in 2026?
Based on GuruFocus' analysis, Cardlytics stock appears to be undervalued.
The current stock price of $3.75 is trading 72.9% below its estimated GF Value™ of $13.84.
GuruFocus considers Cardlytics to be Possible Value Trap.
Key valuation signals for CDLX:
3-Year EPS without NRI Growth Rate: 43.20% (44% above median its 10-year median of 29.90)
GF Value™: $13.84 vs. price of $3.75 (72.9% below fair value)
Industry Position: 1067.6% above the Media - Diversified median (#119 of 713)
No single metric tells the full story. See the CDLX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cardlytics Inc is a commerce media platform that is designed to make commerce smarter and rewarding for everyone. At the core of its commerce media platform is the financial media network that it runs within its partners' digital channels, which includes online and mobile applications (the Cardlytics platform). Additionally, it operates an identity resolution platform that utilizes point-of-sale (POS) data, including product-level purchase data, to enable marketers to perform analytics and targeted loyalty marketing and also measure the impact of their marketing (the Bridg platform). It operates in three segments: the Cardlytics platform in the U.S.; the Cardlytics platform in the U.K.; and the Bridg platform. The majority of the revenue is derived from the Cardlytics platform.
30GF Score
Get the complete analysis for CDLX
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CDLX has been successfully added to your 
